A multiple-dose safety study for healthy adults aged 18–55, run at our Melbourne clinic on behalf of the study sponsor. Around 24 people will take part. We'll explain exactly what the study is evaluating when we speak with you at your screening call.
Three kinds of contact make up the study — two inpatient stays, a series of clinic visits, and a few short phone check-ins.
This study is testing an experimental medicine to find out how safe it is, and how the body absorbs, distributes and clears it, after multiple doses are given by injection under the skin (subcutaneous). It's a Phase 1, first-in-human study — the first time this medicine has been given to people.
You'll receive two doses of the study drug, four weeks apart, across two separate inpatient stays. Some participants will receive the study drug and some will receive placebo — neither you nor the study team will know which, unless it's medically necessary to find out. The study uses a "dose escalation" design: small groups (cohorts of around 8 people) each receive a higher dose than the last, only once the previous dose has been reviewed as safe. Within each group, 6 people receive the study drug and 2 receive placebo.
We won't go into what condition the medicine is being developed for on this page — the study doctor will explain the full background, purpose and any risks in detail during your screening call, before you decide whether to take part.
Payment covers your time, plus travel, parking and meals — you're not out of pocket for taking part.
This is a general guide — full eligibility is confirmed at your screening visit.
